Telehealth stakeholders are upset with the Drug Enforcement Administration’s plan unveiled Friday (Feb. 24) to reimpose some restrictions on telehealth prescribing of controlled substances after the Covid-19 public health emergency ends, and they hope to work with administration officials to come up with what they view as a more balanced approach. When the PHE ends May 11, DEA’s proposed rule would no longer allow for telehealth prescribing of schedule II drugs, including Adderall and other amphetamines, or narcotics like prescription...